2. 2
A Comprehensive Approach
Cord Blood
Stem Cell
Banking
Private Adult Stem
Cell Banking
Public Banking
Cellular
Therapy
Biological Safety Deposit Box
CONFIDENTIAL
FDA
Changing the Model
Cord Blood Banking
3. 3
Pillars of the Business
3 Divisions
FDA drug license
Cord Blood Banking Adult Banking Public Banking
20 years but still “new” to consumers 1st in class
Multibillion dollar market CU partnerships and collaborations
Strong recurring revenues
Possible exclusivity
National programHigh profit potential
CONFIDENTIAL
4. 4
High Potential
Public, Private, and Research
Private Banking Adult Banking
• Twenty years of use and
technical ability
• Multi-billion dollar
consumer business in
place and maturing
• Dominated by marketing
companies
• Strong recurring
revenues
• Opportunity to take
share
• New product
• Market introduction
• High end target
market
• Collections through
blood centers
nationwide
Public
• FDA drug license
• Regenerative
medicine research
• Leverage university
assets
CONFIDENTIAL
5. 5
• 32 acre medical campus
• 6.4 million square feet
• 7,000+ faculty members
• 21,000+ employees
• Serving over 500,000 patients annually
• Established in 1883
University of Colorado
The Medical Campus
CONFIDENTIAL
6. 6
Part of an Integrated Medical Center
The University of Colorado
School of Medicine
Bioengineering and Applied
Science
Bioscience Park
University of Colorado
Hospital
Gates Center for Regenerative
Medicine
Children’s Hospital Colorado
At the University of Colorado
CONFIDENTIAL
Anschutz Medical Campus
7. 7
• Administered by transplant physicians and histocompatibility scientists committed to
improving patient transplant outcomes
• Collecting and banking umbilical cord blood since 1996; accredited by the AABB
• Class 10,000 cGMP stem cell processing facility
• HRSA Contractor for National Cord Blood Inventory (NCBI) since 2006
• Cord blood units are available through the NMDP
• Confirmatory HLA typing
• More than 750 units released for patient transplants
• Units shipped to more than 120 transplant programs in Argentina, Australia, Belgium,
Brazil, Canada, China, France, Italy, Mexico, New Zealand, Spain, United Kingdom, Uruguay,
and the United States
• 50% of units are from minority donors
• FDA License No. 1855, received on May 24th, 2012
Public Cord Blood Banking
Processing Cord Blood Units
under License for 3 Years
Processing Donated Cord Blood
Units for 18 Years
Inventory of 10,000+
Cord Blood Units
FDA License No. 1855, Received May 24th, 2012
CONFIDENTIAL
8. 8
ClinImmuneLabs
At the University Of Colorado
CONFIDENTIAL
Dr. Brian Freed
Executive Director and
Professor at the
University of Colorado’s
School of Medicine
Sharon Miller,
CHS MT
Director of
Regulatory
Affairs
Regulatory
Michael
Aubrey, MS
Chief
Operating
Officer
Operations
Tate
Hermanson
Director of
Business
Services
Administration
Dr. Ralph Quinones
Director of Blood
and Marrow
Processing
Laboratory
Co-Medical Director
Dr. Jonathan
Gutman
Clinical Director
of Allogeneic
Transplantation
Co-Medical Director
Executive Director
9. 9
ClinImmune is Comprised of Six Laboratories
These laboratories provide services to kidney, heart, lung, pancreas, and hematopoietic stem cell
transplant programs including: University of Colorado Hospital, Colorado Children’s Hospital,
Presbyterian/St. Luke’s (Denver, Colorado), Northside Hospital (Atlanta, Georgia), and St. Francis
Hospital (Charleston, South Carolina).
Providing Services to Hospitals Nationwide
Histocompatibility
Clinical Immunology
Flow Cytometry
CariCord
Human Stem Cell Processing
Public Cord Blood Bank is FDA Licensed
18 years
Expertise and Experience
CONFIDENTIAL
10. 10
New Laboratory Opened 2015
CONFIDENTIAL
Largest Medical School Construction Project in the US
At the University of Colorado
In 2013, the University of Colorado Board of Regents approved a new Bioscience 2
facility which will contain our state of the art Class 10,000 cGMP lab. The University
celebrated with a Grand Opening Ceremony on 11/18 2015. The District’s adjacency to
the Anschutz Medical Campus and its formal affiliation with the University of Colorado
provides priority access and support for research and product development.
11. 11
• CariCord is a stem cell services company providing best in class cord blood and tissue preservation,
focused on improving the health, wellness and quality of life of families who choose to save their
baby’s stem cells at birth.
• A component of ClinImmune Labs at the University of Colorado, CariCord combines the latest
scientific research with ongoing feedback from both transplant physicians and the research
community to maintain its cutting edge quality standards within the newborn stem cell storage
market.
• 2014, CariCord launched our initial sales efforts to both the OBGYNs, utilizing an experienced
management team and concurrently direct to consumers, via advertising and a call center with sales
agents. We have seen rapid acceptance of our offering and core messages: Stability, Quality and
Experience.
• 2015, we have built a scalable model and are seeking investment partners to facilitate rapid growth,
as we fuel our market launch and upwards growth trajectory.
About CariCord
A Unique Model with a Strong Message
CONFIDENTIAL
12. 12
ExperiencedLeadershipTeam
Over 50 Combined Years of Cord Blood Industry Knowledge
Calvin Cole
President &
CEO
President
Brian
McEnroe
Sr. VP Sales
& Marketing
Sales and Marketing
Ranelle
Erickson
VP of
Marketing
Marketing
John Gabriel
Sr. VP
Operations
Operations
Dub Sitton
VP
of Sales
Sales
Jim Todd
Chief
Financial
Officer
Finance Global Medical Director
Ratan
Bhardwaj
MD, PhD,
Pediatric
Neurosurgery
Medical Director
Donald
Vliegenthart
MD, Board
Certified
Orthopedic
Surgeon
Scientific
Harry Kloor
PhD, PhD
Chief
Scientific
Officer
CONFIDENTIAL
14. 14
We have been processing cord blood units under federal contract since 2006.
We were among the first to elevate our cord blood banking practices to FDA BLA
licensure. I’m pleased to announce we are the first to leverage our lab’s best
practices to serve private consumers, while sustaining our efforts to build the
National Cord Blood Inventory with life-saving transplant ready units. We believe
our partnership in CariCord demonstrates a sustainable pathway that is responsive
to current and future private and federal sector demands.
“
”
Brian Freed
Executive Director of ClinImmune
Labs and Professor at the University
of Colorado’s School of Medicine
Quality Banking
History of Expertise Now Available to Families
CONFIDENTIAL
15. 15
Cord Blood Banking
Families can choose to preserve their baby’s cord blood at the time of birth, utilizing our temperature
controlled collection kit. Cord blood is currently used to treat over 80 diseases with many more in
research.
Cord Tissue Banking
Families can also choose to save their baby's cord tissue at delivery, using the CariCord collection kit cup,
always available inside our kit. Cord tissue stem cells show promising therapeutic potential in pre-clinical
research for diseases such as stroke, diabetes, Parkinson’s disease, ligament repair in sports injuries, liver
and lung repair and wound healing.
Product Pipeline
Adult Stem Cell Banking is currently under development
and details of the project are confidential at this time.
The project will have broad appeal and will save quality
stem cells, for those who enroll. Announcements regarding
the details are dependent on harvesting, processing and
storage and will be coming in the next 90 -180 days,
if not sooner.
Our Products
Current Offerings
CONFIDENTIAL
16. 16
CariCord’s goal is to become the # 1 cord blood and tissue company recommended by health care providers, to all
patients. We also plan to develop a comprehensive line of stem cell storage options for adult stem cells from
alternative sources. Key elements of the CariCord’s strategy to achieve this goal are as follows:
Our GrowthStrategy
Positioned for Success
Building the National Cord Blood Supply
We plan to combine the private and public cord blood banks and increase the number of donation
hospitals, with a goal of creating large volume, FDA licensed cord blood units, to provide to families and
healthcare professionals seeking lifesaving units for transplant.
Focus on Research
We plan to expand our efforts on research, clinical trials, and commercialization of stem cell related products.
Therapies that improve the quality of life, recovery, and outcomes for diseases treated with stem cells, will
increase the demand for stem cell storage and therapeutic treatment options for patients.
Exclusive Current Market Focus
Initially, we plan to focus exclusively on cord blood and tissue banking, focusing on superior
quality and long term stability, demonstrating to physicians that they can be confident
recommending CariCord to patients and families.
CONFIDENTIAL
17. 17
Class 10,000 clean rooms
Laboratory capacity
Oversight and management
CLINICAL
TRIALS
ClinicalTrialCenter– Researchand Development
Advancing Stem Cell Science
CONFIDENTIAL
COLLABORATION
PATH TO NEW
TREATMENTS
Dedicated partner
Researchers
Academic medical center
Commercialization
Testing for safety and efficacy
Creation of novel cellular products
18. 18
Crag T. Jordan, MD
Dr. Jordan serves as the Chief of the Hematology Division and directs a research program focused on the
development of novel therapies for the treatment of leukemia.
Brian M. Freed, PhD, DABHI
Dr. Freed is Executive Director of ClinImmune Labs and a Professor of Medicine and Immunology. ClinImmune Labs consists of
the Histocompatibility Lab, the Stem Cell Lab, the University of Colorado Cord Blood Bank, the Flow Cytometry Lab and
CariCord. His research focuses on the role of individual HLA amino acid residues in antigen presentation with the goal of
providing HLA-specific immunotherapy.
Johnathan Gutman, MD
Dr. Gutman directs the Allogeneic Bone Barrow Transplant (BMT) program and is a leading expert in the use of
umbilical cord blood derived stem cells for BMT. He oversees a broad range of clinical programs and trials.
Clay Smith, MD
Dr. Smith is the Associate Chief of Hematology and the Clinical Director for the Blood Cancer Program. He is a
highly experienced laboratory researcher and directs a program focused on the development of new therapeutic
regimens in the treatment of hematologic malignancies.
Jill Slansky, PhD
Using an animal model for colon cancer, Dr. Slansky is determining what substitutions in tumor antigen peptides can
be used to improve antitumor immunity. These so-called mimotope peptides (mimics of epitopes) activate T cells
that respond to the tumor more effectively than the natural tumor antigen.
Ross Kedl, PhD
Dr. Kedl is interested in this curious boundary between the innate and adaptive immune systems and seeks to
elucidate signals and pathways emanating from the various families of innate receptors most efficiently mediate the
transition to the adaptive cellular immune response.
Cellular Therapy Team
CONFIDENTIAL
19. 19
Mesenchymal Stem Cells Could Hold the Key to the Future of Ground Breaking Research
There are many areas of preclinical research4,5,6,7,8,9
Sports
Injuries
Lung Disease
Stroke
Liver Repair
Rheumatoid
Arthritis
Parkinson’s
Disease
Type 1
Diabetes
Burn Victims
Extensive Pipeline of Future Stem Cell Applications
Osteoarthritis
More Diseases in Research with Stem Cells
CONFIDENTIAL
21. 21
1.Moise K Jr. Umbilical Cord Stem Cells, Obstetrics Gynecology, 2005; 106(6):1393-1407 2.Nietfield JJ, Pasquini MC, Logan BR, Verter,
Horowitz MM. Lifetime Probabilities of a Hematopietic Stem Cell Transplantation in the US, Biology Blood and Marrow Transplant, 2008;
14:316-322. 3. Based on a 6/6 HLA match. 4. Stroke: Ding DC, Shyu WC, Chiang MF et al. Enhancement of Neuroplasticity through
Upregulation of B1-integrin in Human Umbilical Cord Derived Stromal Stem Cell Implanted Stroke Model, Neurobiology Dis. 2007;
27(3):339-353. E-publication 2007 June 18. 5. Parkinson’s Disease: Fu YS, Cheng YC, Lin MY, et al. Conversion of Human Umbilical Cord
Mesenchymal Stem Cells in Wharton’s Jelly To Dopaminergic Neurons in Vitro: Potential Therapeutic Application For Parkinson’s Disease,
Stem Cells. 2006; 24(1):115-124. E-publication 2005 August. 6.Rheumatoid Arthritis: Liu Y Mu R Wang S et al. Therapeutic Potential of
Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis, Arthritis Res Ther. 2010; 12(6):R210 7. Sports
Injuries (cartilage): Wang L. Tran 1, Seshareddy K et al. A Comparison of Human Bone Marrow-Derived Mesenchymal Stem Cells and
Human Umbilical Cord Derived Mesenchymal Stromal Cells for Cartilage Tissue Engineering, Tissue Eng. 2009; 15(8)(pt A): 2259-2266.
8.Type 1 Diabetes: Anzalone R, Lo Iacono M, Loria T, et al. Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells
Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type
1 Diabetes. Stem Cell Rev. October 23, 2010 E-publication. 9. Lung Cancer: Maurya DK, Doi C, Kawabata A, et al. Therapy With Un-
engineered Naïve Rat Umbilical Cord Blood Matrix Stem Cells Markedly Inhibits Growth of Murine Lung Adenocarcinoma, BMC Cancer,
2010;10-590. 10. Data on file as of February 2014. 11. Accreditations current as of February 2014. 12.Center for Biologics Evaluation and
Research, Food and Drug Administration, US Department of Human and Health Services, Guidance for the Industry: Minimally
Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoetic Reconstitution for Specified Indications,
October 2009. 13. Data on file for CariCord and numbers from company websites ViaCord (268) and CBR (262) as of February 2014. 14.
Discount applies when cord blood and cord tissue banking are chosen with a prepaid storage plan. Prices effective as of February 2014
General Disclaimer: Most of the diseases currently treated with cord blood stem cells are genetic diseases. Banking cord blood does not
guarantee that your physicians will choose it as first line course of treatment over a sibling donor or autologous donor depending on the
diseases being treated and other factors in consideration of a transplant. Only a treating physician can determine when it should be used
on a case by case basis. Cord tissue research is pre-clinical and may have potential in the future but is not used in treatments in humans
currently.
CONFIDENTIAL
